Shares of Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) dropped 0.8% on Friday . The company traded as low as $42.04 and last traded at $42.78, with a volume of 337,336 shares trading hands. The stock had previously closed at $43.14.

EGRX has been the subject of a number of analyst reports. Mizuho dropped their price objective on Eagle Pharmaceuticals from $81.00 to $71.00 and set a “buy” rating for the company in a research note on Friday, March 18th. Piper Jaffray Cos. dropped their price objective on Eagle Pharmaceuticals from $121.00 to $98.00 and set an “overweight” rating for the company in a research note on Friday, March 18th. Royal Bank Of Canada dropped their price objective on Eagle Pharmaceuticals from $100.00 to $94.00 and set an “outperform” rating for the company in a research note on Monday, March 21st. Finally, Zacks Investment Research raised Eagle Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, July 4th. Two analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. Eagle Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $88.94.

The company has a 50 day moving average price of $43.77 and a 200 day moving average price of $53.82. The firm’s market capitalization is $668.91 million.

Eagle Pharmaceuticals (NASDAQ:EGRX) last issued its earnings results on Monday, May 9th. The specialty pharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.46 by $0.52. The company earned $29.60 million during the quarter, compared to the consensus estimate of $29.07 million. The company’s revenue for the quarter was down 18.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.31 earnings per share. On average, equities research analysts expect that Eagle Pharmaceuticals Inc. will post $4.16 EPS for the current fiscal year.

In related news, major shareholder Proquest Management Llc sold 17,980 shares of Eagle Pharmaceuticals stock in a transaction that occurred on Friday, May 13th. The stock was sold at an average price of $40.72, for a total transaction of $732,145.60. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

A number of hedge funds have recently added to or reduced their stakes in EGRX. Century Capital Management LLC increased its stake in Eagle Pharmaceuticals by 34.4% in the fourth quarter. Century Capital Management LLC now owns 66,209 shares of the specialty pharmaceutical company’s stock worth $5,871,000 after buying an additional 16,942 shares during the last quarter. Turner Investments L.P. purchased a new stake in Eagle Pharmaceuticals during the fourth quarter worth about $2,350,000. Bank of Montreal Can increased its stake in Eagle Pharmaceuticals by 62.3% in the fourth quarter. Bank of Montreal Can now owns 119,902 shares of the specialty pharmaceutical company’s stock worth $10,632,000 after buying an additional 46,020 shares during the last quarter. Morgan Stanley increased its stake in Eagle Pharmaceuticals by 192.4% in the fourth quarter. Morgan Stanley now owns 47,523 shares of the specialty pharmaceutical company’s stock worth $4,213,000 after buying an additional 31,273 shares during the last quarter. Finally, JW Asset Management LLC increased its stake in Eagle Pharmaceuticals by 1.1% in the fourth quarter. JW Asset Management LLC now owns 857,679 shares of the specialty pharmaceutical company’s stock worth $76,050,000 after buying an additional 8,970 shares during the last quarter.

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care, orphan diseases and oncology areas. Its commercial products include Argatroban Injection, Ryanodex (dantrolene sodium) for injectable suspension, Diclofenac sodium misoprostol and Docetaxel Injection.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.